These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 26772878)

  • 1. Ligand-targeted theranostic nanomedicines against cancer.
    Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
    J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
    Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
    Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.
    Butler KS; Durfee PN; Theron C; Ashley CE; Carnes EC; Brinker CJ
    Small; 2016 Apr; 12(16):2173-85. PubMed ID: 26780591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane-encapsulated camouflaged nanomedicines in drug delivery.
    Ghosh S; Girigoswami K; Girigoswami A
    Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand decorated biodegradable nanomedicine in the treatment of cancer.
    Ahmad E; Ali A; Fatima MT; Nimisha ; Apurva ; Kumar A; Sumi MP; Sattar RSA; Mahajan B; Saluja SS
    Pharmacol Res; 2021 May; 167():105544. PubMed ID: 33722711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers.
    Kebebe D; Liu Y; Wu Y; Vilakhamxay M; Liu Z; Li J
    Int J Nanomedicine; 2018; 13():1425-1442. PubMed ID: 29563797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators.
    Yang Y; Zhang M; Song H; Yu C
    Acc Chem Res; 2020 Aug; 53(8):1545-1556. PubMed ID: 32667182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
    Liu X; Wu L; Wang L; Jiang W
    Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology Inspired Advanced Engineering Fundamentals for Optimizing Drug Delivery.
    Kassem AA
    Curr Drug Targets; 2018; 19(15):1839-1854. PubMed ID: 29412103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects.
    Adebowale AS; Choonara YE; Kumar P; du Toit LC; Pillay V
    Curr Pharm Des; 2015; 21(22):3167-80. PubMed ID: 26027569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies.
    Howard CB; Fletcher N; Houston ZH; Fuchs AV; Boase NR; Simpson JD; Raftery LJ; Ruder T; Jones ML; de Bakker CJ; Mahler SM; Thurecht KJ
    Adv Healthc Mater; 2016 Aug; 5(16):2055-68. PubMed ID: 27283923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance.
    Wei X; Song M; Li W; Huang J; Yang G; Wang Y
    Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-based active targeting strategies for cancer theranostics.
    Bandyopadhyay A; Das T; Nandy S; Sahib S; Preetam S; Gopalakrishnan AV; Dey A
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3417-3441. PubMed ID: 37466702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor mediated tumor targeting: an emerging approach for cancer therapy.
    Mohanty C; Das M; Kanwar JR; Sahoo SK
    Curr Drug Deliv; 2011 Jan; 8(1):45-58. PubMed ID: 21034422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging.
    Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO
    Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Drug Delivery for the Treatment of Blood Cancers.
    Jiang Y; Lin W; Zhu L
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.